Cita APA

Golan, Y., DuPont, H. L., Aldomiro, F., Jensen, E. H., Hanson, M. E., & Dorr, M. B. (2017). Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients with Substantial Renal Impairment (SRI). Open Forum Infect Dis.

Chicago Style Citation

Golan, Yoav, Herbert L. DuPont, Fernando Aldomiro, Erin H. Jensen, Mary E. Hanson, i Mary Beth Dorr. "Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients With Substantial Renal Impairment (SRI)." Open Forum Infect Dis 2017.

Cita MLA

Golan, Yoav, et al. "Bezlotoxumab (BEZ) for Prevention of Clostridium Difficile Infection (CDI) Recurrence (rCDI): Outcomes in Patients With Substantial Renal Impairment (SRI)." Open Forum Infect Dis 2017.